Targeting Psychosis in Alzheimer’s Disease

Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care impossible is not cognition—it is psychosis. Hallucinations and delusions in Alzheimer’s are a distinct, prevalent, and under-recognized target for therapy. We spoke to Elizabeth Thompson, executive vice president and head of R&D at Acadia Pharmaceuticals, about the biology behind psychosis in dementia, the company’s experimental therapy to treat the condition in people with Alzheimer’s disease, and the forces reshaping the drug development landscape to enable the development of such treatments.

You can listen to Targeting Psychosis in Alzheimer’s Disease online on Radio and Podcast. Open the player on this page to stream the available audio.

Targeting Psychosis in Alzheimer’s Disease is an episode from The Bio Report by Levine Media Group.

This episode is 22:09 long.

This episode was published on Apr 1, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.